Last reviewed · How we verify

NCT04925817

3D Ultrasound Microvessel Imaging for Breast Masses

Completed EARLY_PHASE1 Last updated 7 June 2024
What this trial tests

EARLY_PHASE1 trial testing Electronic Health Record Review in Breast Carcinoma in 50 participants. Completed in 18 May 2023.

Timeline
19 August 2021
Primary endpoint
18 May 2023
18 May 2023

Quick facts

Lead sponsorMayo Clinic
PhaseEARLY_PHASE1
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment50
Start date19 August 2021
Primary completion18 May 2023
Estimated completion18 May 2023
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Mayo Clinic

Who can join

18 and older, female only, with Breast Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This early phase I trial studies how well 3D ultrasound microvessel imaging works for the diagnosis of breast mass. The 3D ultrasound microvessel imaging technology demonstrates significantly increased vessel detection sensitivity over conventional doppler methods without the need of using contrast agents. This study may improve cancer diagnosis and reduce unnecessary biopsy on benign tumors.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Electronic Health Record Review

Trials testing the same drug.

Other recruiting trials for Breast Carcinoma

Currently open trials in the same condition.

Other Mayo Clinic trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04925817.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing